635-19SS Hepatitis C: Completing the Diagnosis with HCV RNA Testing
October 22, 2019 October 22, 2020
Previously Record Webinar
New cases of acute hepatitis C have increased rapidly in the US since 2010, and have most often been associated with injection drug use. Efforts to diagnose and link individuals to care need to significantly increase to reduce the rates of acute HCV infection. The recommended testing algorithm for the diagnosis of HCV requires an initial screen with an HCV antibody test which, if reactive, should be followed by an HCV Nucleic Acid Test (NAT) to detect the viral RNA present in a person with a current infection. This webinar will share the experiences of two jurisdictions that have implemented HCV RNA testing. The presentations will highlight the collaborations between the public health laboratory and the health department from planning to implementation and sustaining testing.
At the conclusion of the program, the participant will be able to:
- Describe the testing algorithm for diagnosis of HCV
- Discuss two approaches to implement HCV NAT testing
Lindsay Jolly MPH, CPH, MLS (ASCP), Immunoserology Supervisor, Division of Laboratory Services, Tennessee Department of Health
Liisa Randall, PhD, Director, Office of Health Care Planning, Massachusetts Department of Public Health
This program is intended for anyone who works in or supervises a public health or clinical laboratory, including clinical and public health laboratory staff as well as anyone who works in or supervises a public health program for hepatitis epidemiology, surveillance or prevention.
The Association of Public Health Laboratories (APHL) is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program, Florida and CPH-recertification. P.A.C.E.® is accepted by all licensure states except Florida. This webinar will provide 1.0 contact hour for participants who successfully complete this training until October 22, 2020. After this date, you can no longer obtain P.A.C.E.® for this webinar.
There are no additional sessions for this event.